LearnGlossaryMarketStocksSuperinvestorsSign in

ACRV

Acrivon Therapeutics, Inc. Common Stock

Healthcare · $90M market cap

Verdict

We can't put a fair value on ACRV right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-27.0% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-58.6%✗

Follow ACRV

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Levin Michaela

Chief Business Officer · 2026-08-31

Award

$272K

Levin Michaela

Chief Business Officer · 2026-08-31

Award

30,000 shares

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works